Xia Wang

Xia Wang

Auto-generated profile, based on publicly available information

Xia Wang

Sun Yat-sen University (SYSU) - Lingnan (University) College

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HXHong-Bin Xu
Hong-Bin Xu
XCXianzhen Chen
Xianzhen Chen
XWXia Wang
Xia Wang
JPJing Pan
Jing Pan
ZYZhao Yi-Zhuo
Zhao Yi-Zhuo
CZChenhui Zhou
Chenhui Zhou

7 February 2025 in Journal of Econometrics
Verified
Journal Article
Closed access
XWXia Wang
Xia Wang
SJSainan Jin
Sainan Jin
YLYingxing Li
Yingxing Li
JQJunhui Qian
Junhui Qian
LSLiangjun Su
Liangjun Su

13 December 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HHHe Huang
He Huang
SXSu Xu
Su Xu
FHFubin Huang
Fubin Huang
XWXia Wang
Xia Wang
YCYong Chen
Yong Chen
ZXZhaoshan Xu
Zhaoshan Xu
Objective. We sought to investigate the efficacy and safety of Infliximab for prevention of postoperative recurrence in patients with Crohn’s disease (CD), in a meta-analysis of clinical trial results. Methods. The Medline, Embase, PubMed, and Web of Science databases were systematically searched for suitable studies. A meta-analysis of enrolled studies was performed to analyze the efficacy of Infliximab on outcomes regarding the prevention of postoperative recurrence of CD. A Galbraith radial plot was used to quantify the heterogeneity. Funnel plot and Egger test were performed to describe the bias of publication. A Forest plot was prepared to indicate the efficacy outcomes. Results. A total of 7 prospective trials were included in our meta-analysis (N=455). The Funnel plot and Egger test showed there was no significant bias in the included publications. The Cochrane collaboration tool indicated that all 7 prospective trials were of high quality. The results of Galbraith radial plot showed that no study was the source of heterogeneity. Compared with the placebo group, Infliximab decreased the rates of endoscopic recurrence (RR =0.421; 95% CI 0.328 to 0.539; p<0.001), and there was a significant reduction in rates of clinical recurrence in the Infliximab-treated group (RR =0.519; 95% CI 0.349 to 0.774; p=0.001). Furthermore, Infliximab treatment did not show adverse effects as other systematic therapeutic drugs, indicating that Infliximab treatment is effective and well tolerated. Conclusion. Compared with the controls, Infliximab is a promising therapeutic agent for the management of CD patients.

23 July 2025 in Journal of Econometrics
Verified
Journal Article
Closed access
LSLiangjun Su
Liangjun Su
SJSainan Jin
Sainan Jin
XWXia Wang
Xia Wang

8 December 2025 in Journal of Time Series Analysis
Verified
Journal Article
Closed access
YCYiqiu Cao
Yiqiu Cao
ZFZhonghao Fu
Zhonghao Fu
YHYongmiao Hong
Yongmiao Hong
XWXia Wang
Xia Wang
XZXingtong Zhang
Xingtong Zhang

7 February 2026 in Journal of Econometrics
Verified
Journal Article
Closed access
ZFZhonghao Fu
Zhonghao Fu
SGShang Gao
Shang Gao
LSLiangjun Su
Liangjun Su
XWXia Wang
Xia Wang